{"gao_id": "GAO-23-107056", "published": "2023-09-19T12:00:00Z", "released": "2023-09-19T08:00:00Z", "summary": "This testimony discusses the key role of Medicare Part D drug coverage in giving beneficiaries access to innovative drug treatments. Coverage is provided by private insurance plans that vary in their costs and lists of covered drugs\u2014known as \"formularies.\" Drug makers may give plans rebates in exchange for preferred placement over competitors on formularies. The rebates may lower premiums, but they don't reduce beneficiaries' payments...", "title": "Medicare Part D: CMS Should Monitor Effects of Rebates on Drug Coverage and Spending", "topics": ["Drug prices", "Pharmacy", "Federal spending", "Pharmacy benefit managers", "Medicare", "Beneficiaries", "Medicare beneficiaries", "Health Care", "Drugs", "Medicare spending", "Prescription drugs", "Price inflation"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-23-107056", "versions": [{"title": "Full Report (12 pages)", "url": "https://www.gao.gov/assets/gao-23-107056.pdf"}, {"title": "Accessible PDF (13 pages)", "url": "https://www.gao.gov/assets/870/861524.pdf"}]}